NASDAQ: RNAAtrium Therapeutics Inc Stock
$12.61-0.14 (-1.1%)
Updated Jun 16, 2026
RNA Price
$12.61
Fair Value Price
-$10.89
Market Cap
$215.70M
52 Week Low
$11.40
52 Week High
$16.77
P/E
N/A
P/B
0.92x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
N/A
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RNA Overview
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RNA
Ranked#132 of 462
Ranked#132 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important RNA news, forecast changes, insider trades & much more!
RNA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNA ($12.61) is overvalued by 215.81% relative to our estimate of its Fair Value price of -$10.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNA ($12.61) is not significantly undervalued (215.81%) relative to our estimate of its Fair Value price of -$10.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more RNA due diligence checks available for Premium users.
Valuation
RNA fair value
Fair Value of RNA stock based on Discounted Cash Flow (DCF)
Price
$12.61
Fair Value
-$10.89
Undervalued by
215.81%
RNA ($12.61) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNA ($12.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.92x
Industry
4.86x
RNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNA's financial health
Profit margin
Revenue
$19.6M
Net Income
-$16.6M
Profit Margin
-84.7%
Assets to liabilities
Assets
$292.4M
Liabilities
$58.3M
Debt to equity
0.25
RNA's short-term assets ($285.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNA's short-term assets ($285.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.1M
Investing
-$2.1M
Financing
$301.5M
RNA vs Biotech Stocks
Atrium Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.